Inhibitor receives orphan designation for PTCL

Print Friendly, PDF & Email


Enteropathy-associated
T-cell lymphoma
Image by Michael Bonert
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to cerdulatinib for the treatment of peripheral T-cell lymphoma (PTCL). Cerdulatinib is an oral Syk/JAK inhibitor being developed by Portola Pharmaceuticals, Inc. Preclinical data have suggested an important role for Syk and JAK in PTCL... [Read Article]
Print Friendly, PDF & Email

Variant not associated with CLL, AIHA, or ITP in certain patients

Print Friendly, PDF & Email


DNA helix
Image by Spencer Phillips
New research suggests there is no association between the PTPN22 R620W polymorphism and chronic lymphocytic leukemia (CLL) or autoimmune hematologic disorders in patients from the Republic of Macedonia. Past studies have shown an association between the PTPN22 R620W variant and both CLL and autoimmune diseases in patients from... [Read Article]
Print Friendly, PDF & Email

System may better predict thrombosis in lymphoma

Print Friendly, PDF & Email


Audience at Leukemia and Lymphoma: Europe and the USA, Linking Knowledge and Practice
An updated scoring system can more accurately identify lymphoma patients who may require thromboprophylaxis, according to researchers. The revised scoring system, ThroLy, proved more effective than other systems for predicting thromboembolic events in lymphoma patients. Researchers found the updated ThroLy had... [Read Article]
Print Friendly, PDF & Email

Duvelisib bests ofatumumab as monotherapy for treatment of CLL/SLL

Print Friendly, PDF & Email


Ian W. Flinn, MD, PhD
Photo from Sarah Cannon
Final analysis of the phase 3 DUO trial has shown monotherapy with oral duvelisib results in a statistically significant improvement in progression-free survival (PFS) and overall response rate (ORR) compared to monotherapy with ofatumumab for patients with relapsed or refractory chronic lymphocytic leukemia/small lympchocytic lymphoma (CLL/SLL).... [Read Article]
Print Friendly, PDF & Email

5-year remission rates with combo prove durable in MCL

Print Friendly, PDF & Email


Mantle cell lymphoma
Long-term results of a phase 2 clinical trial of the lenalidomide and rituximab combination as first-line therapy for mantle cell lymphoma (MCL) show continued durable responses with manageable toxicities after 5 years. With a median follow-up of 64 months, 21 of 33 patients with initial responses remained in durable, minimal residual disease... [Read Article]
Print Friendly, PDF & Email

FDA approves duvelisib for CLL/SLL and FL

Print Friendly, PDF & Email


Micrograph showing CLL
The U.S. Food and Drug Administration (FDA) has approved duvelisib (Copiktra™), a dual PI3K delta/gamma inhibitor, for two indications. Duvelisib has full FDA approval to treat adults with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have received at least two prior therapies. Duvelisib also has accelerated approval to... [Read Article]
Print Friendly, PDF & Email

CHMP supports new indication for venetoclax

Print Friendly, PDF & Email


U.S. version of venetoclax
Photo courtesy of Abbvie
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) approve a new indication for venetoclax (Venclyxto®). AbbVie is seeking EC approval for venetoclax in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic... [Read Article]
Print Friendly, PDF & Email

CHMP recommends mogamulizumab for MF, SS

Print Friendly, PDF & Email


Micrograph showing
mycosis fungoides
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for mogamulizumab (Poteligeo). Kyowa Kirin Limited is seeking European Commission (EC) approval for mogamulizumab as a treatment for adults with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic... [Read Article]
Print Friendly, PDF & Email

CK and TP53 status should be assessed together, team says

Print Friendly, PDF & Email


Mantle cell lymphoma
Researchers say they have found evidence to suggest that patients with mantle cell lymphoma (MCL) should be evaluated for TP53 mutation and complex karyotype (CK) simultaneously before treatment. The team’s study showed that TP53 mutation and CK occurred independently, but patients with both characteristics had poor prognosis. All patients with TP53... [Read Article]
Print Friendly, PDF & Email

Stress linked to disease markers in CLL

Print Friendly, PDF & Email


Micrograph showing CLL
New research has linked stress levels to markers of progressive disease in patients with chronic lymphocytic leukemia (CLL). Researchers found that CLL patients who reported more stress also had higher absolute lymphocyte counts and elevated levels of three other markers of more advanced disease—tumor necrosis factor-α (TNFα), interleukin 16 (IL-16), and chemokine... [Read Article]
Print Friendly, PDF & Email

NICE rejects DLBCL indication for CAR T-cell therapy

Print Friendly, PDF & Email


Tisagenlecleucel (Kymriah)
Photo from Novartis
The National Institute for Health and Care Excellence (NICE) has issued a draft guidance saying it cannot recommend tisagenlecleucel (Kymriah) as a treatment for adults with diffuse large B-cell lymphoma (DLBCL). Tisagenlecleucel is a chimeric antigen receptor (CAR) T-cell therapy that was recently approved by the European Commission (EC) to... [Read Article]
Print Friendly, PDF & Email

Guidelines for proton therapy in mediastinal lymphomas

Print Friendly, PDF & Email


Treatment room at the
Roberts Proton Therapy
Center at the University
of Pennsylvania.
Photo from Penn Medicine
Proton therapy can help mitigate toxicity in adults with mediastinal lymphomas, but the treatment should only be used in patients expected to derive the most benefit, according to new guidelines from the International Lymphoma Radiation Oncology Group. The... [Read Article]
Print Friendly, PDF & Email

Risks of watchful waiting in follicular lymphoma

Print Friendly, PDF & Email


Micrograph showing
follicular lymphoma
A subset of follicular lymphoma (FL) patients managed with watchful waiting are vulnerable to organ dysfunction and transformation, according to research published in Clinical Lymphoma, Myeloma & Leukemia. In a retrospective study, about 24% of FL patients managed with watchful waiting developed significant organ dysfunction or transformation at first progression over... [Read Article]
Print Friendly, PDF & Email